Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential Therapy With WLL/Inhaling GM-CSF in Adult Patients With Severe Autoimmune Pulmonary Alveolar Proteinosis
NCT03316651Phase 2Unknown
- Start
- Aug 2016
- Primary completion
- Dec 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of sargramostim in autoimmune pulmonary alveolar proteinosis (aPAP). Status: unknown.
02
Drugs
sargramostim
03
Conditions
autoimmune pulmonary alveolar proteinosis (aPAP)
Beyond the preview
Go deeper on NCT03316651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03316651.